Author Archives: Ron Renaud

About Ron Renaud

CEO of RaNA Therapeutics; ex-CEO of Idenix

Nucleic Acid Therapeutics: Don’t Hit the Panic Button
November 28, 2016

This blog was written by both Bill Marshall, CEO of MiRagen Therapeutics, and Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Recent news from Alnylam, Ionis, and Mirna Therapeutics regarding toxicity-related setbacks

Leave a comment

Life After The Street: Why Biotech Is Winning Over Wall Street Talent
July 5, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. About three weeks ago, I attended a dinner organized by a good friend and former sell-side competitor, Dr. Yaron

1 Comment

Putting It In Reverse
March 18, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much of the discussion I have had had with my colleagues in publicly traded biotech companies over the last

Leave a comment

A Biotech New Year’s Resolution
December 15, 2015

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is that time of the year again when we start to get ready for the New Year.  It is

2 Comments

The Other Side Of The Fence
August 5, 2015

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In a previous post I was extolling the virtues of leading a private company. Specifically, the freedom of being able

2 Comments

To Tweet Or Not To Tweet, That Is The Question
May 13, 2015

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Have you ever scrolled through your Twitter feed and found something distasteful posted about your company? You may be the

Leave a comment

Public Pool Or Private Beach
February 23, 2015

Three years ago, I was walking across One Kendall Square in pursuit of a late lunch and bumped into a friend – another biotech CEO. I was a year into my role as CEO of Idenix, a publicly traded biotech

2 Comments